1 Min Read
Oct 9 (Reuters) - Entasis Therapeutics Inc
* Entasis Therapeutics highlights positive phase 1 data for ETX2514 at IDWeek 2017, announces plans to advance combination with sulbactam (ETX2514SUL) into Phase 2 trials Source text for Eikon:
All quotes delayed a minimum of 15 minutes. See here for a complete list of exchanges and delays.
© 2018 Reuters. All Rights Reserved.